CD5L and obesity due to melanocortin 4 receptor deficiency: To conclude, the combined application of AIM (i.e., AIM agonists) and anti-AIM (i.e., AIM antagonists) has the potential to serve as a next-generation therapy for preventing harmful obesity-associated inflammatory diseases brought about by modern lifestyles (Fig. 4).